Safety Information
Wegovy Side Effects Explained
Quick Answer: Wegovy (semaglutide 2.4 mg) commonly causes nausea, vomiting, diarrhoea, constipation and stomach pain, particularly during the dose escalation phase. Most side effects are mild to moderate and settle within four to eight weeks as your body adjusts. Serious side effects are rare but include pancreatitis and gallbladder disease.44%of patients report nausea during treatment
4–8 wksfor most side effects to ease significantly
2.4 mgfinal maintenance dose — when symptoms most settle
The Science
Why Does Wegovy Cause Side Effects?
Most side effects are a direct consequence of Wegovy's mechanism of action — not a sign something is wrong. GLP-1 receptors are distributed throughout the gastrointestinal tract. When semaglutide activates these receptors, it slows gastric emptying, which commonly produces nausea, bloating and discomfort. GLP-1 receptors in the brain's nausea centres add a neurological component. The gradual dose escalation schedule exists specifically to reduce the severity of these effects.
Why side effects are dose-dependent
Each dose increase temporarily raises the likelihood of gastrointestinal symptoms as the body recalibrates. Clinical trials demonstrate that side effects peak during dose escalation and diminish significantly once patients stabilise on their maintenance dose.
Common Side Effects (STEP Trial Data)
Week-by-Week Side Effects Timeline
Managing Nausea on Wegovy
Eating smaller meals more frequently is the most effective single intervention. Large meals compound the discomfort caused by slowed gastric emptying. Aim for three to four small meals per day. Foods high in fat, spice, or heavy processing are more likely to trigger nausea and are best minimised during early weeks.
Serious Side Effects — Know the Warning Signs
| Side Effect | Frequency | Typical Onset |
|---|---|---|
| Nausea | 44% | Weeks 1–4 |
| Diarrhoea | 30% | Weeks 1–6 |
| Vomiting | 24% | Weeks 1–4 |
| Constipation | 24% | Weeks 2–8 |
| Abdominal pain | 20% | Weeks 1–8 |
| Headache | 14% | Weeks 1–3 |
| Fatigue | 11% | Weeks 1–6 |
| Indigestion | 9% | Variable |
| Dizziness | 7% | Variable |
| Period | What to Expect |
|---|---|
| Weeks 1–4 (0.25 mg) | Nausea most common, typically peaking around injection day and easing over 48 hours. Mild stomach discomfort and occasional loose stools are normal. |
| Weeks 5–8 (0.5 mg) | Dose escalates. Nausea may temporarily increase. Constipation becomes more common. Headache and fatigue may persist but typically begin to ease. |
| Weeks 9–12 (1.0 mg) | Further escalation. Appetite suppression more pronounced. GI symptoms often settle into a predictable pattern. |
| Weeks 13–16 (1.7 mg) | Penultimate dose step. Nausea may briefly return. Weight loss often accelerates here as appetite is substantially reduced. |
| Week 17+ (2.4 mg) | Maintenance dose. Side effects significantly reduced for most patients. Nausea becomes infrequent. Energy levels often stabilise. |
💧 Hydration
Aim for at least 1.5–2 litres of water daily. Ginger and peppermint tea can help. Sip frequently rather than drinking large volumes at once.
💉 Injection Timing
Some patients inject in the evening so peak side effects occur overnight. Consistency in day and time matters more than the specific time chosen.
Seek urgent medical attention if you experience any of the following
| Symptom | Action |
|---|---|
| Severe abdominal pain radiating to the back | Seek urgent attention — possible pancreatitis |
| Upper right abdominal pain after eating | Contact GP — possible gallbladder issue |
| Swelling of face, lips or throat | Call 999 immediately — severe allergic reaction |
| Signs of dehydration (dizziness, dark urine) | Seek medical attention and increase fluids |
| Significant mood change or depression | Contact your GP or mental health professional |
Happy Pharmacy Clinical Support: All Happy Pharmacy patients have access to clinical support throughout treatment. Our GPhC-registered pharmacists are available to advise on side effect management, dose adjustments and when to seek further medical review.
FAQs
Frequently Asked Questions: Wegovy Side Effects
The most common Wegovy side effects are nausea (44%), diarrhoea (30%), vomiting (24%), constipation (24%) and abdominal pain (20%). These are all gastrointestinal in nature and arise because semaglutide slows stomach emptying and activates GLP-1 receptors throughout the gut. Headache and fatigue are also common, particularly in the first few weeks. The majority ease significantly as the dose escalates and the body adapts.
For most patients, side effects are most pronounced during the first four to eight weeks and at each dose escalation step. By the time patients reach the 2.4 mg maintenance dose — around week 17–20 — side effects have usually reduced substantially. A minority experience persistent mild nausea throughout treatment, but this rarely requires discontinuation.
Yes, for the vast majority of patients. Nausea is most common during dose escalation and typically improves once the body adapts to each dose level. By the maintenance phase at 2.4 mg, most patients report that nausea has resolved or occurs only occasionally. Dietary strategies — smaller meals, avoiding fatty foods, staying hydrated — can significantly reduce nausea during the adjustment period.
Constipation on Wegovy is a direct consequence of slowed gastric emptying — semaglutide reduces the speed at which food moves through the digestive system. Staying well hydrated, eating adequate dietary fibre, and maintaining light physical activity can all help. If it becomes troublesome, speak to your pharmacist.
A small proportion of patients notice temporary hair thinning. This is most commonly attributed to rapid weight loss and calorie restriction rather than to semaglutide itself — a condition known as telogen effluvium. Hair growth typically returns within six months without any specific treatment.
The majority of patients who experience side effects do not need to discontinue treatment. In the STEP 1 trial, around 7% of participants discontinued due to gastrointestinal side effects. A slower escalation schedule or temporary dose pause can help patients who find side effects difficult to manage.
Ready to Start Wegovy Treatment?
GPhC-registered pharmacy · UK-licensed prescribers · Free online assessment
Check Your Eligibility →
Clinical references: Davies M et al. STEP 1. N Engl J Med. 2021;384:989–1002. MHRA. Semaglutide (Wegovy) prescribing information. 2023. NICE TA875. 2023. Happy Pharmacy (GPhC No. 9012585). This page is for educational purposes only and does not constitute medical advice.